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To evaluate the effects of simple compensated fixed-dose
iodine-131 therapy for thyrotoxicosis, the long-term results
for 74 patients treated with a fixed dose ofiodine-131 ranging
from 5 to 12 mCi (185 to 444 MBq) were evaluated in the first
2 years of a trial. The dose selected was loosely based on the
gross size of the thyroid gland. Routine antithyroid drug
therapy was given for a minimum of 3 months after iodine-
131 therapy. The mean (± SD) duration offollow-up was 74.5
± 42 months. The results indicated that roughly 25% of
patients treated in this way will become hypothyroid after 5
years and that 85% are cured (need no further therapy during
the follow-up period) using a single dose of iodine-131. Of
those cured using a single iodine-131 dose, 81% were no
longer receiving drugs after 6 months and 85% after 1 year.
Such a regimen seems currently to be among the best available
where prolonged periods of medication-free euthyroidism
after therapy are sought.
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INTRODUCTION
Although spontaneous remission of clinical
thyrotoxicosis has been recorded, the vast
majority of patients ultimately require surgery
or iodine-131 therapy. There are two basic
approaches to dosing in iodine-131 therapy-
ablative and non-ablative. Ablative therapy
usually aims at using a fixed dose near the
upper limit of the therapeutic range and
results in a high incidence of early
hypothyroidism. This approach has not gained
widespread acceptance because of uncertainty
about the frequency of default, the numbers of
non-compliant patients who later discontinue
thyroxine, the adequacy and efficiency of
follow-up, or possible complications, such as
cancer of ischaemic heart disease.':" In non-
ablative therapy, lower doses of iodine-131
are administered in an effort to minimize the
occurrence of hypothyroidism, and reduced
incidences of hypothyroidism result. This
approach, however, has been associated with
an increased incidence of treatment failure
and prolonged morbidity due to hyper-
thyroidism. It is now known that lower rates
of hypothyroidism and lower incidences of
treatment failure are mutually exclusive, and
that hypothyroidism is an inevitable
consequence of iodine-131 therapy since it
appears that the risk of thyroid failure
continues for life, even with the lowest
reported doses of iodine-131. The best
approach, therefore, is to strike a balance
between the two courses and offer the patient
the maximum possible period of euthyroidism,
which can be of great value, especially in the
elderly.
Low-dose regimens have essentially either
used fixed doses or have utilized various
parameters to estimate an ideal delivered
dose of radiation to the thyroid. Compensated
delivered dose regimens have also been
formulated in which the delivered dose is
titrated for the size of the thyroid gland;
however, the estimation of the radiation dose
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delivered to the thyroid gland is complicated
and attempts to use estimates of these
measurements in the individual patient have
all suffered from the same basic flaw: the
assumption that all the important differences
between individuals regarding iodine-131
dosimetry can be predicted from the individual
factors involved, usually gland mass and
iodine-131 uptake.
Although some of the individual variability
is generally ascribable to these factors, other
factors may be more important. It has been
shown, for example, that there is an uneven
distribution of radiation through the thyroid
gland" and it has been calculated that there
could be a 10o-fold difference between the
highest and lowest dose received in anyone
gland." Estimating the overall size of the
thyroid is also thwart with difficulties and
determining the cellular mass of a particular
thyroid gland is even more problematical
since amounts offibrous and interstitial tissue,
and the volume of relatively radio-resistant
colloid all vary.' As a consequence, the
clinician cannot assume that the predicted
delivered dose, based on the estimated thyroid
gland mass and iodine-131 uptake, will be
attained in a particular patient; in general, the
dosage delivered by the various methods of
individualizing therapy can be no more than
an estimate. Furthermore, even if dosimetry
were standardized, individual sensitivity to
iodine-131 varies" and is as yet unquantifiable.
A regimen was, therefore, introduced in
the University Hospital, University of
Malaysia, Kuala Lumpar in late 1979 that
aimed to provide a reasonably good period of
medication-free euthyroidism coupled with a
reasonably low failure rate based on a rough
estimate of the delivered radiation dose.
Reported below are the preliminary results of
long-term follow-up of the first group of
patients treated with what may be termed a
compensated fixed-dose regimen.
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PATIENTS AND METHODS
PATIENTS
Hyperthyroid patients included in the present
study were referred to the University Hospital,
Kuala Lumpar, during the period 1979 -1981
for further management of thyrotoxicosis. The
diagnosis of hyperthyroidism was based on
clinical findings in conjunction with elevated
serum thyroxine concentrations, resin uptake
and, in some cases, thyroid uptake studies.
STUDY DESIGN
Patients had, in general, first been treated
with a full course of antithyroid medication
(carbimazole or propylthiouracil for at least 1
year), being considered for iodine-131 therapy
after they relapsed. The iodine-131 was
delivered to patients in approximately
euthyroid state, as far as possible. All
medication was discontinued 7 days before
therapy (since it is documented that
antithyroid drugs decrease the amount of
iodine in the thyroid gland') and 7 days after
therapy patients were recommenced on
antithyroid medication for 3 months (10
mg/day carbimazole or 100 mg/day propyl-
thiouracil), after which medication was
stopped. Patients who still showed symptoms
of thyrotoxicosis after stopping the drugs
were given further drugs for up to about 24
months, when retreatment with iodine-131
was carried out.
The therapeutic dose of iodine-131 was
based on the size of the gland alone. The
uptake studies previously performed and the
presence of nodularity in the gland on
palpation were disregarded for dosage
purposes. Goitres were classified on a grading
scale of 0- III:grade 0, no clinically detectable
(or just palpable) goitre; grade I, mild enlarged
goitre; grade II, moderately enlarged goitre;
and grade III, excessively enlarged goitre. The
weight of the thyroid gland was roughly
estimated based on the assumption that
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common clinically detectable goitres are in
the range 20-100 g. It was, therefore, assumed
that grade I goitres would weigh about 40 g
and grade II goitres about 80 g. Fixed doses of
5,7,10 and 12 mCi, respectively, were given
to grades 0, I, II and III goitres. Patients who
were eventually given further treatment were
treated with a different dose. Hypothyroidism
was established on the basis of clinical signs
in conjunction with an elevated serum
concetration of thyroid-stimulating hormones.
The patients were followed up once every
3 months for the first year, thereafter, the
patient was assessed every 6 monthes if he/she
remained enthyroid.
STATISTICAL ANALYSIS
Data were analysed by the Kaplan - Meier
product limit method," which indicates the
probability of hypothyroidism during the
follow-up years rather than the actual number
of cases occurring in the group of patients
treated in the individual years. This was
preferred to the actuarial (life table) methods
since it overcomes bias if there are a large
number of withdrawals and ifwithdrawals do
not occur mid-way in a time interval. Bivariate
comparisons of nominal data were made using
Fisher's exact test because small sample sizes
were encountered in the retreated group.
Comparisons of continuous variables in two
samples were made with the Mann - Whitney
or Wilcoxon two-sample test.
RESULTS
A total of 74 patients were surveyed, of whom
16 (21.6%) were male and 58 (78.4%) female,
and the mean (± SD) age was 46.9 ± 7.9 years.
Of these patients, 64 (86.5%) required only a
single dose of iodine-131, eight (10.8%)
received two doses, one (1.4%) three doses
and one (1.4%) four doses. The mean (± SD)
duration of follow-up for the whole group was
74.5 ± 42 months. The numbers of patients
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with diffuse goitre, multinodular goitre,
uninodular goitre and no goitre were 49
(66.2%), 15 (20.3%), two (5.4%) and one
(1.4%), respectively; the remaining five
patients were unclassified. A total of nine
(12.2%) of the patients had undergone surgical
treatment (sub-total thyroidectomy). The mean
interval between diagnosis and first iodine-
131 therapy was 45.6 ± 50.4 months (range <
1 - 204 months). The ethnic origins of the
patients included in the study were 59 (79.7%)
Chinese, 10 (13.5%) Malay and five (6.8%)
Indian.
Bivariate comparisons of the single-dose
and retreated patients showed that in the
Malay patients there was a higher incidence
of retreatment than in either the Chinese
group alone, or the Chinese and Indians
combined; the minimum follow-up period
was 3 years. There was no statistically
significant difference in the sex distribution,
the sizes of goitres, or the surgical status of
patients who did or did not need retreatment.
Comparisons of the mean age, initial dose and
interval between diagnosis and therapy also
showed no statistically significant differences
between the two treatment groups. The mean
(± SD) initial doses ofiodine-131 were 8.34 ±
1.8 mCi (308.6 ± 66.6 MBq) for the single-dose
group and 8.6 ± 2.1 mCi for the repeated-dose
group.
The proportion of the original group
followed-up at each month after therapy and
the corresponding probability of thyroid
failure in that month are shown in Fig. 1 for
the single-dose group. Overall, there was a
consistent fall in the proportion of patients
remaining in the study of about 80% per year
(n = 0.98); the mean duration offollow-up was
69.9 months (median 68 months) in the group
given one dose only. The mean (± SD) period
of antithyroid drug therapy was 8.0 ± 15
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months (median and mode, 3 months; 75
percentile, 5 months) for those given only one
dose of iodine-131 (minimum follow-up
period 1 year). The mean period of antithyroid
medication following the second dose of
iodine-131 (for those receiving two doses
only) was 2.0 ± 1.7 months. Retreatment was
carried out in a mean (± SD) of 23.2 ± 9.2
months after therapy range (8 - 40 months). Of
those given two doses of iodine-131, five
(62.5%) became hypothyroid in a mean (± SD)
time of 16.8 ± 16.0 months; the remaining
three (37.5 %) were euthyroid for mean periods
of up to 75.5± 27.0 months when they were
lost to follow-up. Among patients with a
minimum follow-up of3 years the retreatment
rate was 15% (cure rate, 85%). Cumulative
incidences of hypothyroidism at 3.5 years
and 5.5 years were 5.7% (95% confidence
interval, 1-12%) and 22.2% (95% confidence
interval, 9 - 35.4%), respectively, for those
given only one dose ofiodine-131 (Fig. 2). The
percentages of patients that have survived
without developing hypothyroidism are
shown in Fig. 3.
DISCUSSION
The reasons for the considerable loss of
patients to follow-up are unclear, although
the drop-out rate was similar to that in a
previously reported study in which the mean
follow-up was 74 months and the median 60
months." It seems likely that patients who
develop hypothyroidism are more likely to
attend and those that do not are predominantly
euthyroid. It cannot, however, be assumed
that this is so, because other authors have
attempted to relocate lost patients and reported
that the incidence of hypothyroidism in this
default group was the same as that in the
patients who had been followed up
5.7%/year (5-9 years)2.5%/year (1- 5 years)
100 -
90
80
70
~ 60
U)
50"E
C1l
~ 40
o,
30
20
10
0
0 2 3 4 5 6 7
Time after therapy (years)
8 9 10 11
Cumulative percentage of thyrotoxicosis patients that became hypothyroid after
iodine-131 treatment among the group that needed only a single dose of iodine-131.
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continuously." Attempts are currently being
made to recall defaulters in the present study
for further analysis.
The results of the present long-term study
do not indicate any remarkable differences
between the responses to therapy in patients
with multinodular or diffuse goitres, although
there has always been a wide variation of
views about the appropriate treatment for
toxic nodular goitre. The results of the present
study are consistent with those of previous
studies," in which patients with nodular
goitres were more frequent and I-year cure
rates were relatively unaffected by gland type
(impalpable, diffuse, or nodular) or post-
operative status of the patients. Cure rates of
66 - 73% (overall 69%) have been reported in
all these clinical groups following iodine-131
doses estimated to deliver 7000 rads to the
thyroid." In the present study, four patients
had a uninodular goitre, one of whom required
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three doses of iodine-131 , one was cured with
one dose (and remained euthyroid for 114
months) and the other two were not followed
up sufficiently to determine their outcome.
Non-ablative therapy has commonly been
administered in two forms, either as a fixed
dose of radioiodine or as a dose estimated to
deliver a predetermined amount ofradiation.
For the latter method, it has been suggested
that the administered amount of iodine-131
given should ideally deliver a radiation dose
of6000-7000 rads (60 -70 Gy), and 7000 rads
has become regarded as a conventional
dose.'2.1:1 Following the administration of such
iodine-131 doses in pa lients with
thyrotoxicosis, 60 - 70% of patients have
been reported to be euthyroid within 1 year
after a single dose, the remaining patients
needing retreatment."·12 1415 Within 6 months
of the initial dose, roughly one-half of the
patients can be expected to be rendered
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euthyroid, with roughly 10 - 20% more
achieving euthyroidism within the year.
"
, 14 , W
This cure rate is comparable to that of the
present regimen where 81 % of those receiving
one dose of iodine-131 were receiving no
medication and 69% were euthyroid after 6
months, and 85% were not receiving drugs
and were euthyroid after 1 year, Rates of
hypothyroidism after 1 or 2 years for patients
given iodine-131 doses estimated to deliver
7000 rads have been have been reported to be
approximately 10%,111,,]4 wh ich is comparable
to an upper limit on the 95% confidence
interval of 5 - 9% in the present study. The
late incidence rate of hypothyroidism after 10
years has been reported to be relatively
constant at about 2 - 4.5% per year for iodine-
131 doses ranging from 25 to 200 IJCilg of
thyroid.vt'Tn this study, the rate in the first 5
years was 2.5 % per year and, in the subsequent
4 years, was 5.7% per year. The rise in rates of
hypothyroidism in the later years seems to be
consistent with the suggestion that the patients
lost to follow-up were predominantly
euthyroid.
Compensated radiation dose therapy, as
opposed to fixed-dose therapy, was originally
developed following the finding that doses
estimated to deliver a fixed amount of radi-
ation to the thyroid resulted in rates of
hypothyroidism that were highest in those
with small goitres and decreased with
increasing goitre size, in.rn An analysis of the
response to first treatment in relation to the
estimated weight of the thyroid gland in one
of the previous studies did show a statistically
significant rise in the percentage of patients
remaining hyperthyroid with increasing gland
mass!' and thus also supported the view that
compensation for gland mass was required.
Com pensated doses, in general, delivered 3000
- 5000 rads since more than 90% of the
patients reported were estimated to have
glands weighing less than 50 g, and these
doses resulted in cure rates of approximately
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66 - 76% after about 1 year. lO ,2 0 Other
compensated low-dose regimens (average dose
probably in the same range as those above)
reported cure rates of 83% at 1 year (including
the 10% of patients who were hypothyroid at
1 year).'" Only 64% of patients, however,
were cured without the need for additional
therapy; 19% required supplementary anti-
thyroid drug therapy before eventually
becoming euthyroid at 1 year. '0 Most patients
given antithyroid medication will eventually
no longer be hyperthyroid. There is, however,
no advantage in giving regimens that require
additional prolonged antithyroid medication
as these patients will also eventually become
hypothyroid (albeit over a longer period of
time). in Not much difference has been reported
in the rates of hypothyroidism obtained with
earlier compensated regimens compared with
non-compensated regimens; both regimens
resulted in I-year rates of hypothyroidism of
approximately 10%.,,,,1'],,,, Neither compen-
sated nor non-compensated estimated radi-
ation dose therapy, therefore, showed superior
results to the present study utilizing fixed
doses (with compensation only for the
approximate gland weight).
Although the lower rate of hypothyroidism
expected for the compensated regimens
compared with non-compensated ones was
not discernible, non-compensated dosing
regimens that on the average delivered similar
doses to those compensated regimens have
resulted in poorer outcomes. In one study
where iodine-131 was given at a dose of 50 j.lCi
retained at 24 hlg of thyroid tissue
(approximatley 4000 rad anticipated dose),
there was a 7.1% incidence of hypothyroidism
and a cure rate of 46% at 1 year (i.e, 54% of
patients were still hyperthyroid at 1 year).'"
Another study, in which roughly 3500 rads
were delivered, similar results were observed,
with 65% of patients being hyperthyroid after
1 year and a rate of hypothyroidism of 4.3% .'2
Better outcomes have, however, been reported
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from other low-dose studies. In one such
study where slightly higher doses were given
(80 llCi per estimated g of thyroid tissue was
given, mean radiation absorbed dose 5578
rads), 74% of patients were cured and 6%
were permanently hypothyroid after a mean
follow-up period of 19 ± 6 months." Higher
cure rates were observed in this study possibly
because of the routine administration of
potassium iodide and, perhaps, the use of of
higher iodine-131 dosages.
It may, therefore, be inferred that
compensation for the size of the gland may
increase the ability of a particular dose to
bring about a cure. The reason why the rates
of hypothyroidism induced by the consequent
lower doses of iodine-131 are not lower is
probably due to the fact that rates rise much
faster for increases in doses above 7000 rads.
This phenomenom has also been observed
using fixed doses: after a iodine-131 dose of 2
mCi (74 MBq) 6% of patients were reported to
be hypothyroid after 1 year" and after a fixed
5mCi (185MBq) dose 15.5% were hypothyroid
at 1 year." Following a 10 mCi dose, however,
61 - 69% were hypothyroid at 1 year."·'{; By
contrast, as the radioactivity dose is varied,
the cure rates at 1 year are less markedly
affected. After the administration of 2 mCi (74
MBq) iodine-131, cure has been reported to be
55% at 1 year (excluding those that relapsed
later, for whom the cure was 62%)'" and,
among patients treated with fixed doses of 3
- 10 mCi iodine-131, 76.2% were cured,
patients being considered to be cured if the
functional status at 1 year was either euthyroid
or hypothyroid without further treatment for
hyperthyroidism during the year)."
Classifying of these patients according to the
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dose administered resulted in no significant
increase in the proportion cured by 3 - 5 mCi,
but there was a significant increase with the
administration of 5 - 10 mCi iodine-131 (5
mCi iodine-131, 70% cure rate; 10 mCi iodine-
131, 87% cure rate}." This is in agreement
with other studies utilizing fixed iodine-131
doses of 5 mCi (185 MBq), in which the cure
rate was 72%24 and following 10 mCi (370
MBq) iodine-131 81 - 88% of patients were
reported to be cured at 1 year. 2 5.' fi Increasing
the dose above 10 mCi did not result such big
increases in cure rate as did the increase from
5 to 10 mCi iodine-131." A compensated
fixed dose in the range 5 - 10 mCi thus seems
to offer the best chance for lower rates of
hypothyroidism combined with good cure
rates. The results of the present study, and of
parallel approaches to therapy ,r. are consistent
with this conclusion.
The vast number of different approaches to
minimizing post-iodine-131 hypothyroidism,
and the similarities of the results obtained,
provides one of the primary reasons why
there is still no conventionally accepted
regimen for iodine-131 in the treatment of
thyrotoxicosis. It seems that real progress in
this field must await the methodological
breakthroughs that will increase under-
standing of the biology of Graves's disease
and the interaction of that biology with
radiation-induced aberrations at the
subcellular level.' In the meantime, the
present therapeutic regimen offers a simple
approach to therapy and may provide a good
balance between hypothyroidism and
treatment failure in patients with
thyrotoxicosis where prolonged periods of
euthyroidism are sought.
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